Assessment of the safety and effectiveness of neoadjuvant camrelizumab and apatinib in conjunction with chemotherapy for stage IIIA (N2) non-small cell lung cancer: Results from a multi-center, single-arm phase II study - Takeaways - MDSpire

Assessment of the safety and effectiveness of neoadjuvant camrelizumab and apatinib in conjunction with chemotherapy for stage IIIA (N2) non-small cell lung cancer: Results from a multi-center, single-arm phase II study

  • By

  • Lilan Zhao

  • Tianxing Guo

  • Yi Zhang

  • Zhen Huang

  • Yangyun Huang

  • Lihuan Zhu

  • Xing Chen

  • Nan Zhang

  • Liren Guo

  • Rongzhi Huang

  • Guojun Geng

  • Ning Li

  • Shuxing Chen

  • Xiaojie Pan

  • Wenshu Chen

  • October 24, 2025

  • 0 min

Share

  • 1

    The study evaluates the safety and effectiveness of camrelizumab and apatinib combined with chemotherapy for stage IIIA non-small cell lung cancer.

  • 2

    Neoadjuvant therapy aims to reduce tumor size and eliminate micrometastases before surgery, potentially improving surgical outcomes.

  • 3

    Participants included patients aged 18 to 75 with histologically confirmed stage IIIA NSCLC and adequate organ function.

  • 4

    The treatment regimen involved 2–4 cycles of camrelizumab, chemotherapy, and apatinib, followed by surgery 4 to 6 weeks post-treatment.

  • 5

    The study highlights the need for innovative therapeutic approaches to enhance outcomes for patients with locally advanced NSCLC.

Original Source(s)

Assessment of the safety and effectiveness of neoadjuvant camrelizumab and apatinib in conjunction with chemotherapy for stage IIIA (N2) non-small cell lung cancer: Results from a multi-center, single-arm phase II study

  • by Lilan Zhao, Tianxing Guo, Yi Zhang, Zhen Huang, Yangyun Huang, Lihuan Zhu, Xing Chen, Nan Zhang, Liren Guo, Rongzhi Huang, Guojun Geng, Ning Li, Shuxing Chen, Xiaojie Pan, Wenshu Chen

  • October 24, 2025

Related Content

Validation of a cervical CDO1/CELF4 methylation test for endometrial cancer: a prospective paired-sample comparison with intrauterine specimen

Immune biomarker landscape and fusion partner–phenotype associations in thoracic and head-and-neck NUT carcinoma

The role of NAD+ metabolic reprogramming in colorectal cancer chemoresistance: mechanistic insights, clinical translation challenges and opportunities